Influence of the Duffy Antigen on Pharmacokinetics and Pharmacodynamics of Recombinant Monocyte Chemoattractant Protein (MCP-1, CCL-2) in Vivo

Monocyte chemoattractant protein-1 (MCP-1, CCL-2) binds to the Duffy antigen (DARC) on red blood cells, which act as a sink for several chemokines including MCP-1. In this study it is hypothesized that DARC may alter the pharmacokinetics of infused recombinant human MCP-1 (rhMCP-1). The primary aim of this first in man trial is to compare the pharmacokinetics of rhMCP-1 in Duffy positive and negative individuals. A randomized, double-blinded, placebo-controlled dose escalation trial was conducted on 36 healthy volunteers. Subjects received infusions of 0.02–2.0 μg/kg rhMCP-1 or placebo for one hour. RhMCP-1 displayed linear pharmacokinetics. Duffy negative individuals reached maximal plasma levels significantly earlier, but overall plasma concentration profiles were not altered. rhMCP-1 markedly increased monocyte counts, and estimated EC50 values were 10-fold higher in Duffy positive than in Duffy negative subjects. Increased monocyte counts were associated with decreased surface expression of intercellular adhesion molecule 1 (ICAM-1, CD54). In contrast, neither CCR-2 or CD11b expression, nor markers of platelet or endothelial activation, inflammation and coagulation were altered. RhMCP-1 is a highly selective chemoattractant for monocytes in humans. The Duffy antigen only minimally alters the pharmacokinetics of rhMCP-1 for doses up to 2 μg/kg.

[1]  C. Papadopoulou,et al.  The role of the chemokines MCP-1, GRO-α, IL-8 and their receptors in the adhesion of monocytic cells to human atherosclerotic plaques , 2008, Cytokine.

[2]  J. Leitner,et al.  Duffy antigen modifies the chemokine response in human endotoxemia , 2008, Critical care medicine.

[3]  J. Regensteiner,et al.  Established and evolving medical therapies for claudication in patients with peripheral arterial disease , 2006, Nature Clinical Practice Cardiovascular Medicine.

[4]  J. Leitner,et al.  Recombinant human antithrombin inhibits thrombin formation and interleukin 6 release in human endotoxemia , 2006, Clinical pharmacology and therapeutics.

[5]  E. Boerwinkle,et al.  Plasma MCP-1 level and risk for peripheral arterial disease and incident coronary heart disease: Atherosclerosis Risk in Communities study. , 2005, Atherosclerosis.

[6]  G. Lip,et al.  Platelet microparticles and soluble P selectin in peripheral artery disease: Relationship to extent of disease and platelet activation markers , 2005, Annals of medicine.

[7]  N. Akimitsu,et al.  Man, mouse and Duffy genotype–phenotype‐specific pharmacokinetics of monocyte chemotactic protein‐1 , 2004, Transfusion medicine.

[8]  B. Jilma,et al.  Effect of interleukin-6 blockade on tissue factor-induced coagulation in human endotoxemia , 2004, Critical care medicine.

[9]  O. Wagner,et al.  E-Selectin and restenosis after femoropopliteal angioplasty: prognostic impact of the Ser128Arg genotype and plasma levels , 2003, Thrombosis and Haemostasis.

[10]  Gregory Y H Lip,et al.  The adhesion molecule P-selectin and cardiovascular disease. , 2003, European heart journal.

[11]  H. Kotani,et al.  Adiposity Elevates Plasma MCP-1 Levels Leading to the Increased CD11b-positive Monocytes in Mice* , 2003, Journal of Biological Chemistry.

[12]  G. Lip,et al.  Soluble E-selectin in cardiovascular disease and its risk factors , 2003, Thrombosis and Haemostasis.

[13]  D. Cook,et al.  Ethnic differences in circulating soluble adhesion molecules: the Wandsworth Heart and Stroke Study. , 2003, Clinical science.

[14]  Janet S. Lee,et al.  References Subscriptions Permissions Email Alerts Duffy Antigen Facilitates Movement of Chemokine Across the Endothelium In Vitro and Promotes Neutrophil Transmigration In , 2013 .

[15]  M. Voskuil,et al.  Modulation of collateral artery growth in a porcine hindlimb ligation model using MCP-1. , 2003, American journal of physiology. Heart and circulatory physiology.

[16]  H. Kusuhara,et al.  A role of the Duffy antigen for the maintenance of plasma chemokine concentrations. , 2003, Biochemical and biophysical research communications.

[17]  M. Voskuil,et al.  Local Monocyte Chemoattractant Protein-1 Therapy Increases Collateral Artery Formation in Apolipoprotein E–Deficient Mice but Induces Systemic Monocytic CD11b Expression, Neointimal Formation, and Plaque Progression , 2003, Circulation research.

[18]  H. Eichler,et al.  Pharmacodynamics of active site‐inhibited factor VIIa in endotoxin‐induced coagulation in humans , 2002, Clinical pharmacology and therapeutics.

[19]  W. Mayr,et al.  Fy phenotype and gender determine plasma levels of monocyte chemotactic protein , 2001, Transfusion.

[20]  I E Hoefer,et al.  Time course of arteriogenesis following femoral artery occlusion in the rabbit. , 2001, Cardiovascular research.

[21]  P. Kolattukudy,et al.  Monocyte chemotactic protein 1 upregulates IL-1beta expression in human monocytes. , 2000, Biochemical and biophysical research communications.

[22]  H. Eichler,et al.  Paroxetine decreases platelet serotonin storage and platelet function in human beings , 2000, Clinical pharmacology and therapeutics.

[23]  J. Hogg,et al.  Expression of the cell adhesion molecules on leukocytes that demarginate during acute maximal exercise. , 1999, Journal of applied physiology.

[24]  I. Charo,et al.  Decreased lesion formation in CCR2−/− mice reveals a role for chemokines in the initiation of atherosclerosis , 1998, Nature.

[25]  P. Libby,et al.  Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. , 1998, Molecular cell.

[26]  H. Eichler,et al.  Dexamethasone down‐regulates the expression of L‐selectin on the surface of neutrophils and lymphocytes in humans* , 1997, Clinical pharmacology and therapeutics.

[27]  T. Byers,et al.  Black/white differences in leukocyte subpopulations in men. , 1997, International journal of epidemiology.

[28]  W. Schaper,et al.  Monocyte chemotactic protein-1 increases collateral and peripheral conductance after femoral artery occlusion. , 1997, Circulation research.

[29]  K. Murao,et al.  Regulation of Expression of the Human Monocyte Chemotactic Protein-1 Receptor (hCCR2) by Cytokines* , 1997, The Journal of Biological Chemistry.

[30]  D L Sackett,et al.  Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review. , 1996, Circulation.

[31]  J. Van Damme,et al.  Adhesion molecule expression and response to chemotactic agents of human monocyte‐derived macrophages , 1996, Clinical and experimental immunology.

[32]  K. Vaddi,et al.  Regulation of monocyte integrin expression by beta-family chemokines. , 1994, Journal of immunology.

[33]  R. Horuk,et al.  Identification and characterization of a promiscuous chemokine-binding protein in a human erythroleukemic cell line. , 1994, The Journal of biological chemistry.

[34]  R. Horuk,et al.  Expression of the Duffy antigen in K562 cells. Evidence that it is the human erythrocyte chemokine receptor. , 1994, The Journal of biological chemistry.

[35]  D. Graves,et al.  Monocyte chemoattractant protein-1 regulates adhesion molecule expression and cytokine production in human monocytes. , 1992, Journal of immunology.

[36]  D Rodbard,et al.  Statistical quality control and routine data processing for radioimmunoassays and immunoradiometric assays. , 1974, Clinical chemistry.